Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Telomir Pharmaceuticals, Inc.

NASDAQ: TELO · Life Sciences · 5 alerts · CIK 1971532

Share price
$0.4810Close, Nov 16
Market cap
$35.4M
Shares outstanding
73.68MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Telomir Pharmaceuticals, Inc. filings on SEC EDGAR ↗

8:31 AM ET 8-K
Clinical Trial Data

Telomir Pharmaceuticals Clinical Trial Data

Telomir Pharmaceuticals announced the publication of peer-reviewed preclinical data in the International Journal of Molecular Sciences demonstrating that Telomir-Zn restored visual function and retinal structure in a model of age-related macular degeneration (AMD). The study showed that 14 days of oral treatment significantly improved visual performance, reduced mitochondrial oxidative stress, and increased telomeric DNA content. While the company remains focused on its Phase 1/2 clinical trial for triple-negative breast cancer, these findings suggest the drug's metal-dependent epigenetic biology may have broader applications beyond oncology.

8:01 AM ET 8-K
Clinical Trial Data

Telomir Pharmaceuticals Clinical Trial Data

Telomir Pharmaceuticals announced positive preclinical in-vitro research findings demonstrating that its compound Telomir-Zn inhibited cell growth in both human and canine osteosarcoma models. The study, conducted with The Ohio State University, showed consistent anti-tumor activity at low drug concentrations, supporting a potential parallel development pathway for veterinary and human oncology indications.

Counterparty
The Ohio State University College of Veterinary Medicine

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.